370 related articles for article (PubMed ID: 24261697)
1. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
5. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L; Stummer W; Senner V; Brokinkel B
Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
[TBL] [Abstract][Full Text] [Related]
7. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
8. ARID1A and TERT promoter mutations in dedifferentiated meningioma.
Abedalthagafi MS; Bi WL; Merrill PH; Gibson WJ; Rose MF; Du Z; Francis JM; Du R; Dunn IF; Ligon AH; Beroukhim R; Santagata S
Cancer Genet; 2015 Jun; 208(6):345-50. PubMed ID: 25963524
[TBL] [Abstract][Full Text] [Related]
9. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
[TBL] [Abstract][Full Text] [Related]
10. hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.
Fürtjes G; Köchling M; Peetz-Dienhart S; Wagner A; Heß K; Hasselblatt M; Senner V; Stummer W; Paulus W; Brokinkel B
J Neurooncol; 2016 Oct; 130(1):79-87. PubMed ID: 27465278
[TBL] [Abstract][Full Text] [Related]
11. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.
Mirian C; Duun-Henriksen AK; Juratli T; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Møller Pedersen M; Law I; Broholm H; Cahill DP; Brastianos P; Poulsgaard L; Fugleholm K; Ziebell M; Munch T; Mathiesen T
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):378-387. PubMed ID: 32041819
[TBL] [Abstract][Full Text] [Related]
12. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.
Zhang X; Jia H; Lu Y; Dong C; Hou J; Wang Z; Wang F; Zhong H; Wang L; Wang K
Discov Med; 2014 Dec; 18(101):301-311. PubMed ID: 25549701
[TBL] [Abstract][Full Text] [Related]
14. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Juratli TA; McCabe D; Nayyar N; Williams EA; Silverman IM; Tummala SS; Fink AL; Baig A; Martinez-Lage M; Selig MK; Bihun IV; Shankar GM; Penson T; Lastrapes M; Daubner D; Meinhardt M; Hennig S; Kaplan AB; Fujio S; Kuter BM; Bertalan MS; Miller JJ; Batten JM; Ely HA; Christiansen J; Baretton GB; Stemmer-Rachamimov AO; Santagata S; Rivera MN; Barker FG; Schackert G; Wakimoto H; Iafrate AJ; Carter SL; Cahill DP; Brastianos PK
Acta Neuropathol; 2018 Nov; 136(5):779-792. PubMed ID: 30123936
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
[TBL] [Abstract][Full Text] [Related]
16. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.
Mirian C; Grell K; Juratli TA; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Jensen LR; Schackert G; Broholm H; Scheie D; Cahill DP; Brastianos PK; Skjøth-Rasmussen J; Fugleholm K; Ziebell M; Munch TN; Kristensen BW; Mathiesen T
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12773. PubMed ID: 34799864
[TBL] [Abstract][Full Text] [Related]
17. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
18. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
19. High incidence of TERT mutation in brain tumor cell lines.
Johanns TM; Fu Y; Kobayashi DK; Mei Y; Dunn IF; Mao DD; Kim AH; Dunn GP
Brain Tumor Pathol; 2016 Jul; 33(3):222-7. PubMed ID: 26960334
[TBL] [Abstract][Full Text] [Related]
20. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
